Marvai Lifesciences Sees FY23 Adj. EPS $0.04-$0.08 vs $0.29 Est., Revenue $300M-$325M vs $403.92M Est.
Portfolio Pulse from Benzinga Newsdesk
Marvai Lifesciences has projected its FY23 adjusted EPS to be between $0.04 and $0.08, which is significantly lower than the estimated $0.29. The company also expects its revenue to be between $300M and $325M, falling short of the estimated $403.92M.
August 07, 2023 | 9:21 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Marvai Lifesciences' lower than expected FY23 EPS and revenue projections could negatively impact its stock price in the short term.
Marvai Lifesciences' FY23 EPS and revenue projections are significantly lower than estimates. This could lead to a negative sentiment among investors, potentially causing a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100